NCT07263711 Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction
| NCT ID | NCT07263711 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2030-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2025-09-01 with a primary completion date of 2030-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical study is to learn if an artificial intelligence (AI) model can accurately predict important molecular changes in gliomas, a type of brain tumor, using digital pathology images. The main questions this study aims to answer are: How accurate is the AI model in predicting key molecular alterations compared with standard molecular testing? Can the AI model shorten the time needed for diagnosis and reduce the need for expensive molecular tests? Researchers will collect whole slide images from multiple hospitals and use the AI model to predict molecular results. The predictions will be compared with the actual test results from standard laboratory methods. Participants will: Allow the use of their pathology images and molecular test results for research. Have no additional treatments or procedures beyond standard medical care. This study will help determine whether AI-assisted tools can provide faster and lower-cost molecular diagnosis for glioma, improving patient care and supporting equal access to precision medicine.
Eligibility Criteria
Inclusion Criteria: * Participant (or legally authorized representative) has voluntarily signed the informed consent form. * Age ≥ 18 years at the time of enrollment. * Histologically suspected diffuse glioma based on biopsy or surgical resection. * Availability of complete clinical information and usable digital pathology slides with hematoxylin and eosin (H\&E) staining. * Postoperative molecular pathology results available for comparison. Exclusion Criteria: * Poor-quality pathology samples (e.g., insufficient tissue, large folding or contamination of slides, or substandard digital scanning quality). * Determined by the investigator to be unsuitable for participation in the study for any reason.
Contact & Investigator
LI LIANG
STUDY DIRECTOR
Nanfang Hospital, Southern Medical University
Frequently Asked Questions
Who can join the NCT07263711 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07263711 currently recruiting?
Yes, NCT07263711 is actively recruiting participants. Contact the research team at lidanyi26@163.com for enrollment information.
Where is the NCT07263711 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07263711 clinical trial?
NCT07263711 is sponsored by Nanfang Hospital, Southern Medical University. The principal investigator is LI LIANG at Nanfang Hospital, Southern Medical University. The trial plans to enroll 2,000 participants.